# A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia

> **NCT07681440** · — · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 30 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Beta-thalassemia

## Interventions

- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT07681440
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-16
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Insufficient enrollment
- **Last updated:** 2026-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07681440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07681440, "A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07681440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*